Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Brawijaya Majalah Kesehatan FKUB Journal of Islamic Medicine
Sumarta, Norma Hanifah
Unknown Affiliation
Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
HUBUNGAN ANTARA PENANDA sCD28 DAN sCTLA-4 TERHADAP PERSENTASE SEL LIMFOSIT T CD8+CD45RA+ PADA PENUAAN IMUN: - Handono, Kusworini; Susanti, Hani; Pratama, Mirza Zaka; Kalim, Handono; Wahono, Caesarius Singgih; Ria Famuji, Siti Roziah; Firdaningrum, Nimas Eka; Sumarta, Norma Hanifah; Rizky Fachry, Ade Wlidan
Majalah Kesehatan Vol. 10 No. 4 (2023): Majalah Kesehatan
Publisher : Faculty of Medicine Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/majalahkesehatan.2023.010.04.1

Abstract

Penuaan merupakan proses alami dan kompleks yang ditandai dengan penurunan fungsi fisiologis manusia sehingga berakibat pada perubahan sistem imun. Sampai saat ini, deteksi penuaan imun (immunosenescence) masih memiliki kendala yang berarti. Penanda satu-satunya yang diyakini sebagai prediktor penuaan imun adalah immune risk profile (IRP). Namun, IRP hanya dapat diamati dengan pemeriksaan flowsitometri yang membutuhkan alat canggih dan keterampilan khusus. Oleh karena itu, diperlukan penelitian yang menemukan suatu penanda deteksi penuaan imun melalui metode yang lebih mudah. Beberapa marker kostimulator memiliki bentuk terlarut di dalam serum. Penanda CD28 dan CTLA-4 pada membran memainkan peran utama pada regulasi aktivasi limfosit T dan marker diagnostik pada autoimun ataupun penuaan imun. Meskipun demikian, bentuk terlarut dari penanda tersebut masih belum banyak diteliti.  Tujuan dari penelitian ini adalah meneliti keterkaitan antara penanda sCD28 dan sCTLA-4 terhadap persentase IRP sel limfosit T CD8+CD45RA+ pada penuaan imun. Molekul kostimulator sCD28 dan sCTLA4 diukur menggunakan ELISA, sedangkan persentase sel limfosit T CD8+CD45RA+ menggunakan flowsitometri. Pada penelitian ini didapatkan 87 responden terdiri dari 23,0% responden kelompok individu muda, 40,2% kelompok pasien Lupus Eritematosus Sistemik (LES), dan 36,8% responden kelompok lansia. Kadar sCD28 dan sCTLA-4 terhadap persentase sel limfosit T CD8+CD45RA+ memiliki hubungan yang tidak signifikan pada penuaan imun. Pada penuaan imun, fungsi sel limfosit T yang mengekspresikan CD45RA menampilkan cacat proliferatif dan pensinyalan, tetapi tetap polifungsional.
Successful Intravitreal Injection of Ranibizumab for Age-Related Macular Degeneration (AMD) in Young Adults: A Case Report Adnani, Basyar; Sumarta, Norma Hanifah; Famuji, Siti Roziah Ria; Khotimah, Alif Raudhah Husnul; Halim, Putri Aulawiya Rosyida; Hasan, Yuliono Trika Nur; Hutasoit, Lina Puspita
Journal of Islamic Medicine Vol 8, No 1 (2024): JOURNAL OF ISLAMIC MEDICINE EDISI MARET 2024
Publisher : Faculty of Medicine and Health Science, Universitas Islam Negeri Maulana Malik Ibrahim

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18860/jim.v8i1.25838

Abstract

Background:  Age Related Macular Degeneration (AMD) is a chronic condition that specifically affects the central retina and is widespread in developed nations. The hypothesis suggests that as the population ages, the occurrence and impact of AMD will rise due to the significant risk factor of being over 55 years old, which is most prevalent among the elderly. Bevacizumab, ranibizumab, and aflibercept have established themselves as the gold standard of therapy. Case Report:  We present the case of a middle-aged man with age-related macular degeneration (AMD) and no concomitant diseases who showed remarkable improvement after intravitreal injection with patizra (ranibizumab). A 44-year-old Asian man was administered Patizra injections for three consecutive months after developing age-related macular degeneration. After intravitreal injection of ranibizumab, this patient's health markedly improved, as seen by a reduction in subretinal fluid. Conclusion:  The intravitreal injection of ranibizumab has demonstrated efficacy in the treatment of age-related macular degeneration in middle-aged adults.
The Role of Soluble Costimulatory Molecules as the Biomarkers for Aging Predictors Handono, Kusworini; Pratama, Mirza Zaka; Susianti, Hani; Wahono, Cesarius Singgih; Firdaningrum, Nimas Eka; Famuji, Siti Roziah Ria; Sumarta, Norma Hanifah; Rizky Fachry, Ade Wildan; Poetri, Levrita Nindya; Kalim, Handono
Jurnal Kedokteran Brawijaya Vol. 32 No. 3 (2023)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2022.032.03.4

Abstract

This study aimed to determine the role of the soluble costimulatory molecules in aging and the association with the presence of comorbid in aged individuals. Thirty-two elderly and twenty healthy subjects were included in this study. The soluble costimulatory molecules sCD28, sCD80, sCD86, sCD163, and sCTLA4 were measured using ELISA. The presence of comorbid was documented from medical records. Charlson Comorbidity Index (CCI) was measured to evaluate the survival/mortality risk for the subjects. The levels of the majority of soluble costimulatory molecules significantly increased in the elderly participants, while the level of sCD86 was comparable. There were weak positive correlations between the subject's age and levels of sCD28 (R=0.214, p=0.048), sCTLA4 (R=0.238, p=0.041), and sCD80 (R=0.317, p=0.012). sCD80 were discovered to be the best to predict immune aging in the elderly with AUC 0.71 [0.57-0.86], sensitivity 53,1%, specificity 80.0%, and cut off 129ng/ml. Most of the elderly participants had at least one comorbid, in which approximately 25.0% and 3.1% of the subjects were classified as mild and moderate CCI. Multivariate analysis showed that comorbidities in elderly individuals have been associated with levels of sCTLA4 ≥26.5ng/ml and sCD80 ≥129.0ng/ml. Furthermore, subjects with comorbid (CCI ≥1) were associated with sCD80 ≥129.0ng/ml (OR 12.44 [95% CI 1.32–117.03], p=0.027). Considering these results, sCD28, sCTLA4, and sCD80 can be developed as biomarkers for predicting immune aging and elderly comorbidities, respectively.
Co-Authors Adnani, Basyar Famuji, Siti Roziah Ria Firdaningrum, Nimas Eka Halim, Putri Aulawiya Rosyida Handono Kalim Hani Susanti, Hani Hani Susianti Hutasoit, Lina Puspita Khotimah, Alif Raudhah Husnul Kusworini Handono Poetri, Levrita Nindya Pratama, Mirza Zaka Ria Famuji, Siti Roziah Rizky Fachry, Ade Wildan Rizky Fachry, Ade Wlidan Wahono, Caesarius Singgih Wahono, Cesarius Singgih Yuliono Trika Nur Hasan